An observational study in Bone Neoplasms, sponsored by Bayer. Completed at 1 site in Czech Republic. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-06.
Sponsored by Bayer · Observational
The effect of Bonefos on consumption of analgesics (drugs used for pain treatment) in patients with proven bone metastases.
322 studies on the registry are indexed under Bone Neoplasms; 81 are open to participants now.
This study's enrollment of 149 is above the median of 75 across 93 observational studies indexed under Bone Neoplasms.
Browse Bone Neoplasms studies →Bayer is the lead sponsor of 1,643 studies on the registry; 57 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 129 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Random sample of cancer patients visting oncologist or urologist ambulance who are suitable for standard clodronate treatment.
Exclusion Criteria:
Drug: Bonefos (Clodronate, BAY94-8393)
Patients in regular clinical practice receiving Bonefos according to local drug information
Analgesics consumption after 12 months of treatment with Bonefos in patients with bone metastases and breast or prostate cancer or multiple myeloma
Time frame: 12 months
Decrease in pain measured by VAS (Visual Analogue Scale)
Time frame: 12 months
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bayer